TOday’s Movers: EDAP TMS (NASDAQ:EDAP) Stock Rating Reiterated at H.C. Wainwright; $6.5000 Target Price Indicates 161.04 % Potential

May 16, 2018 - By Adrian Mccoy

EDAP TMS S.A. (NASDAQ:EDAP) Logo

EDAP TMS (NASDAQ:EDAP) Rating Reaffirmed

Equity research analysts at H.C. Wainwright now has a $6.5000 target price on EDAP TMS (NASDAQ:EDAP). H.C. Wainwright and their recent target price gives a potential upside of 161.04 % from the company’s close price. The rating has been disclosed in an analyst report on Wednesday morning.

The stock increased 2.47% or $0.06 during the last trading session, reaching $2.49. About 34,545 shares traded. EDAP TMS S.A. (NASDAQ:EDAP) has declined 8.41% since May 17, 2017 and is downtrending. It has underperformed by 19.96% the S&P500.

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company has market cap of $72.21 million. The firm operates in two divisions: High Intensity Focused Ultrasound , and Urology Devices and Services (UDS). It currently has negative earnings. The HIFU division develops, makes, and markets devices for the minimally invasive destruction of various types of localized tumors using HIFU technology.

More recent EDAP TMS S.A. (NASDAQ:EDAP) news were published by: Seekingalpha.com which released: “EDAP’s (EDAP) CEO Marc Oczachowski on Q1 2018 Results – Earnings Call Transcript” on May 15, 2018. Also Nasdaq.com published the news titled: “EDAP TMS SA : EDAP Reports 2018 First Quarter Results” on May 14, 2018. Nasdaq.com‘s news article titled: “EDAP TMS SA : EDAP TMS SA to Announce First Quarter 2018 Financial Results on Monday, May 14” with publication date: May 02, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: